The reverse split authorization is a necessary but non-catalytic step to address Nasdaq non-compliance. The board retains discretion not to implement the split, and the actual ratio will be set later. Monitor the stock price trajectory toward the January 25, 2027 deadline — if the price does not recover organically, the split will likely be executed at the high end of the range (1-for-25).
Price Chart
Executive Summary
Tenaya Therapeutics is soliciting stockholder approval for a reverse stock split (ratio between 1-for-10 and 1-for-25) to regain compliance with Nasdaq's minimum bid price requirement. The company received a non-compliance notice on January 28, 2026, and has until January 25, 2027, to meet the $1.00 per share closing bid price for 10 consecutive days. The stock closed at $0.38 per share on the record date, making the reverse split a critical measure to avoid delisting.
Key Facts
- Stock price was $0.38 per share on the record date (October 19, 2026), well below the $1.00 Nasdaq minimum bid price requirement
- Nasdaq non-compliance notice received January 28, 2026; company transferred to Nasdaq Capital Market on July 31, 2026, with a compliance deadline of January 25, 2027
- Board seeks authorization for a reverse stock split ratio between 1-for-10 and 1-for-25, with the exact ratio to be determined by the board
- 227,928,240 shares of common stock outstanding as of the record date
- The Column Group entities beneficially own 32.25% of outstanding shares; Integrated Core Strategies (Millennium) owns 5.08%
- CEO Faraz Ali beneficially owns 1.34% of shares; all executive officers and directors as a group own 2.69%
- 125,061,149 shares reserved for warrant exercise; 22,923,708 shares reserved for equity plan awards
- Authorized shares (1 billion common, 200 million preferred) will remain unchanged after the split
Financial Impact
No direct financial impact; reverse split is a capital structure adjustment. The company faces delisting risk if it cannot achieve $1.00 bid price by January 25, 2027.
Risk Factors
- Reverse stock splits often fail to sustainably increase stock price; many companies see post-split prices decline after the initial adjustment
- Delisting from Nasdaq would severely impair liquidity and access to capital, potentially triggering adverse consequences for a clinical-stage biotech
- Reduced share count may increase odd-lot ownership and transaction costs for retail holders
- The board may choose not to implement the split, leaving the company at risk of delisting
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001193125-26-430591 |
| Document: 0001193125-26-430591-index-headers.html | 0001193125-26-430591 |
| Document: 0001193125-26-430591-index.html | 0001193125-26-430591 |
| Document: 0001193125-26-430591.txt | 0001193125-26-430591 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEFA14A | $0.3945 | awaiting T+60 | — | $0.4151 (+5.22%) |
Oct 23, 2026 3d ago | DEF 14A | $0.3850 | awaiting T+60 | — | $0.4151 (−7.82%) |
Aug 17, 2026 10w ago | 144 | $0.6990 | awaiting T+60 | — | $0.4151 (+40.62%) |
Jul 2, 2026 16w ago | 8-K | $0.7869 $0.5898 | ▼ −25.05% | ▼ −28.62% | $0.4151 (−47.25%) |
Jun 29, 2026 17w ago | 8-K | $0.7349 $0.6822 | ▼ −7.17% | ▼ −11.56% | $0.4151 (−43.52%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.7118 $0.6634 | ▲ +6.80% | ▲ +10.06% | $0.4151 (+41.68%) |
May 29, 2026 21w ago | 8-K | $0.8700 $0.7014 | ▼ −19.38% | ▼ −20.61% | $0.4151 (−52.29%) |
May 19, 2026 22w ago | Insider Cluster | $0.8080 $0.7281 | ▼ −9.89% | ▼ −14.89% | $0.4151 (−48.63%) |
Apr 16, 2026 27w ago | DEFA14A | $0.7470 $0.8365 | ▲ +11.98% | ▲ +4.94% | $0.4151 (−44.43%) |
Mar 11, 2026 32w ago | 8-K | $0.8930 $0.7280 | ▼ −18.48% | ▼ −29.17% | $0.4151 (−53.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers